BioPharma Finder 5.0 Release Notes

Importance of the topic

Characterizing biotherapeutic molecules such as proteins and oligonucleotides is critical for ensuring safety, efficacy, and regulatory compliance in pharmaceutical development. Detailed mass spectrometry–based workflows provide insights into sequence confirmation, post-translational modifications (PTMs), host cell protein impurities, and structural variants. An integrated informatics platform accelerates data processing, enhances confidence in attribute assignment, and supports collaborative review across global teams.

Goals and overview

BioPharma Finder 5.0 is designed to simplify and streamline comprehensive attribute characterization of biotherapeutics. The release focuses on:

• Enhanced throughput and confidence for peptide mapping and intact mass analyses.
• New modules for oligonucleotide mapping and top-down sequencing.
• Integrated host cell protein (HCP) analysis and multi-attribute method (MAM) development.
• Collaborative data processing, version control, and standardized reporting in a connected environment.

Methodology and workflows

BioPharma Finder 5.0 supports multiple analytical workflows:

• Oligonucleotide Analysis: In silico digestion and mapping of mRNA, custom RNase selection, coverage mapping, MS2 prediction for sequence confirmation, and automatic impurity detection.
• Peptide Mapping Analysis: MS2-based amino acid confirmation, PTM identification and quantitation, disulfide bond mapping, error-tolerant and de novo searches for sequence variants and low-level impurities.
• Host Cell Protein Analysis: Combined peptide mapping and HCP database searching (e.g., CHO, human), with automated quantitation reports and selection of representative peptides.
• Intact Mass Analysis: Deconvolution under native or acidic conditions using Xtract and ReSpect algorithms, sliding-window detection of low-abundance species, batch comparisons, glycosylation and ADC identification, and sequence-free mass annotation.
• Top-Down Analysis: ProSightBP™-driven sequencing of intact proteins with support for CID, HCD, ETD, EThcD, and UVPD fragmentation and interactive proteoform comparison.

Used instrumentation

BioPharma Finder operates within a software ecosystem:

• Mass spectrometry data input from Thermo Scientific Orbitrap and other MS platforms.
• HyperBridge™ software for centralized secure data storage and collaboration.
• Chromeleon™ CDS 7.3.1 for chromatography control, data acquisition, and compliance.
• Windows 10 (64-bit), .NET 4.8, Microsoft Office 365, and Adobe Acrobat for report generation.

Main results and discussion

Key advances in version 5.0 include:

• End-to-end peptide mapping with dynamic report designer templates (PDF/XLS), custom calculations, and interactive coverage maps.
• Robust HCP quantitation integrated into the peptide mapping workflow, reducing manual review time.
• Expanded oligonucleotide support, including terminal truncation searches and novel MS2 prediction algorithms for base modifications.
• Improved deconvolution accuracy and speed via sequence-specific isotope tables and sliding-window detection of low-level modifications and ADC species.
• Collaborative versioning history for peptide results and automated trend analysis tools for longitudinal studies.

Benefits and practical applications

BioPharma Finder 5.0 delivers:

• Faster method development and result finalization through built-for-purpose data curation tools.
• Standardized and shareable reporting templates to support regulatory submissions and internal QA/QC.
• Enhanced data integrity via shared sign-on, secure cloud-connected workflows, and centralized data storage.
• Scalable processing across local or virtual private cloud environments for global collaboration.

Future trends and opportunities

Emerging directions in biopharma informatics include:

• Artificial intelligence–driven spectral interpretation to accelerate de novo sequencing and PTM discovery.
• Expanded multi-attribute method (MAM) automation for real-time quality monitoring in manufacturing.
• Integration with laboratory information management systems (LIMS) and electronic lab notebooks (ELNs) to streamline data traceability.
• Support for next-generation fragmentation methods and higher-resolution instruments to probe complex proteoforms and conjugates.
• Advanced cloud-native architectures enabling larger cohort analyses and cross-site data sharing.

Conclusion

BioPharma Finder 5.0 represents a significant step toward unified, high-confidence characterization of biotherapeutics. By combining comprehensive workflows for peptide, oligonucleotide, intact mass, and top-down analyses with secure cloud connectivity and robust reporting tools, the platform empowers analytical teams to accelerate development, ensure product quality, and meet evolving regulatory demands.

References

None provided in original release notes.